Patents by Inventor B. Jack Longley

B. Jack Longley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8278067
    Abstract: This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treating contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a method of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: October 2, 2012
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: B. Jack Longley
  • Publication number: 20120114575
    Abstract: This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treating contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a method of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.
    Type: Application
    Filed: March 15, 2011
    Publication date: May 10, 2012
    Inventor: B. Jack Longley
  • Patent number: 7906302
    Abstract: This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: March 15, 2011
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: B. Jack Longley
  • Patent number: 7846909
    Abstract: Method for inhibiting tumor cell formation or tumor cell growth, and method for inducing apoptosis in sperms, the method comprising administering to a patient in need thereof an antagonist that inhibits the binding of MAGE protein to KAP-1, thereby inhibiting MAGE gene function. Also disclosed are pharmaceutical compositions comprising the same, and method for screening a substance that inhibits MAGE protein binding to KAP-1.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: December 7, 2010
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: B. Jack Longley, Bing Yang, Jianqiang Wu, Yongsheng Ma
  • Publication number: 20090136497
    Abstract: This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a method of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.
    Type: Application
    Filed: November 10, 2008
    Publication date: May 28, 2009
    Inventor: B. Jack Longley
  • Publication number: 20090062226
    Abstract: Method for inhibiting tumor cell formation or tumor cell growth, and method for inducing apoptosis in sperms, the method comprising administering to a patient in need thereof an antagonist that inhibits the binding of MAGE protein to KAP-1, thereby inhibiting MAGE gene function. Also disclosed are pharmaceutical compositions comprising the same, and method for screening a substance that inhibits MAGE protein binding to KAP-1.
    Type: Application
    Filed: December 13, 2007
    Publication date: March 5, 2009
    Inventors: B. Jack Longley, Bing Yang, Jianqiang Wu, Yongsheng Ma
  • Patent number: 7449309
    Abstract: This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a method of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: November 11, 2008
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: B. Jack Longley
  • Patent number: 6989248
    Abstract: This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a methods of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.
    Type: Grant
    Filed: December 29, 1999
    Date of Patent: January 24, 2006
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: B. Jack Longley
  • Patent number: 6977159
    Abstract: This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a method of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: December 20, 2005
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: B. Jack Longley
  • Publication number: 20050265997
    Abstract: Method for inhibiting tumor cell formation or tumor cell growth, and method for inducing apoptosis in sperms, the method comprising administering to a patient in need thereof an antagonist that inhibits MAGE gene expression or MAGE protein function. Preferably, the antagonist is an anti-MAGE antibody, an antisense molecule, an siRNA molecule, a molecule for forming a triplex nucleic acid molecule with a MAGE encoding polynucleotide, or a small molecule inhibitor of MAGE function. Also disclosed are pharmaceutical compositions comprising the same, and method for screening a substance that inhibits MAGE gene expression of MAGE protein function.
    Type: Application
    Filed: May 26, 2005
    Publication date: December 1, 2005
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: B. Jack Longley, Bing Yang
  • Publication number: 20040005623
    Abstract: The present invention provides a new method for predicting whether or not a tumor (cancer, sarcoma, melanoma, etc.) in a patient will respond to a specific drug known to inhibit an enzyme that contributes to the pathogenesis of that type of tumor. The method involves conducting a comparative analysis between the enzymatic site of a reference enzyme known to interact with the drug and the enzymatic site of a target enzyme produced by the tumor cells of the patient. Identification of differences between the alleles of the two enzymes thus provides a basis for determining whether or not the drug will interact with the target enzyme in the tumor cells of the patient so as to inhibit its contribution to the pathogenesis of the tumor.
    Type: Application
    Filed: June 10, 2003
    Publication date: January 8, 2004
    Inventor: B. Jack Longley
  • Patent number: 6576812
    Abstract: The present invention provides a method of identifying a composition, a compound or a procedure which can produce a skin response in a subject, and a method of identifying a composition, a compound, or a procedure which can reduce or treat skin response in a subject. The present invention further provides a method of identifying a composition, a compound, or a procedure which can reduce radiation damage to the skin of a subject, and a pharmaceutical composition for treating human skin diseases.
    Type: Grant
    Filed: May 6, 1999
    Date of Patent: June 10, 2003
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: B. Jack Longley
  • Publication number: 20020123031
    Abstract: This invention provides a method of preventing or treating in a subject contact dermatitis which comprises administering to the subject an amount of a compound capable of inhibiting the stem cell factor signaling pathway effective to prevent or treat contact dermatitis so as to thereby prevent or treat contact dermatitis in the subject. This invention also provides a methods of preventing or treating in a subject hyperpigmentation, asthma, cutaneous inflammation, anaphylaxis and bronchospasm, mastocytosis, tumors which express activated kit, and conception.
    Type: Application
    Filed: December 29, 1999
    Publication date: September 5, 2002
    Inventor: B. JACK LONGLEY
  • Patent number: 6339100
    Abstract: A method of preventing or treating in a subject mastocytosis which comprises administering to the subject a therapeutically effective amount of a compound having the structure: or a pharmaceutically acceptable salt thereof so as to thereby prevent or treat mastocytosis in the subject.
    Type: Grant
    Filed: December 29, 1999
    Date of Patent: January 15, 2002
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: B. Jack Longley